AAIC 2025 Abstract
Blood‐Based Biomarkers in the Lecanemab Patient Pathway for Early Alzheimer’s Disease in the United States
Study in peopleBiomarkers
Papers by Michael Henry Rosenbloom
7 results
- AAIC 2025 Abstract
Real‐World Insights on the Lecanemab Patient Pathway in Early Alzheimer’s Disease in the United States
Study in peoplePopulations - AAIC 2025 Abstract
Real‐World Use of Lecanemab in APOE ε4 Homozygotes and in Patients on Antithrombotic Therapy
Study in peopleInterventions - AAIC 2025 Abstract
Real‐World Use of Lecanemab With Consideration of Race, Ethnicity, and Geographical Diversity
Study in peoplePopulations
- AAIC 2025 Abstract
Real‐World Use of Lecanemab in Patients With Early Alzheimer’s Disease in the United States: a Case Series Review
Study in peopleInterventions - AAIC 2025 Abstract
Real World Lecanemab Outcome Data at 6 months in an Academic Healthcare System
Study in peopleInterventions